Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
Healthcare
$6.77 +1.96%
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
52W Low $3.92High $19.15
Volume 0.02M
Average 1.40M
Income Statement
Follow revenue through to earnings.
Revenue
$120.77M
FY 2025 · Annual
-6.3% YoYOperating Income
$35.86M
FY 2025 · Annual
Net Income
$32.69M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.34M | 63.57M | 8.57M | 128.94M | 120.77M |
| Cost of Revenue | 282M | 269.99M | 8.89M | 21.01M | 21.21M |
| Gross Profit | (261.66M) | (206.42M) | (313K) | 107.93M | 99.56M |
| Gross Margin | -1286.4% | -324.7% | -3.7% | 83.7% | 82.4% |
| Research & Development | 282M | 272.53M | 224.79M | 151.48M | 37.45M |
| Selling, General & Admin | 78.8M | 68.13M | 50.91M | 39.89M | 26.25M |
| Operating Expenses | 78.8M | 74.1M | 275.69M | 191.37M | 63.7M |
| Depreciation & Amortization | 9.35M | 5.65M | 4.83M | 5.05M | 2.12M |
| EBITDA | (330.75M) | (222.26M) | (266M) | (75.75M) | 38.63M |
| EBITDA Margin | -1626.1% | -349.6% | -3102.7% | -58.7% | 32.0% |
| Operating Income | (340.46M) | (280.51M) | (276.01M) | (83.44M) | 35.86M |
| Operating Margin | -1673.9% | -441.2% | -3219.5% | -64.7% | 29.7% |
| Interest Income | 367K | 3.06M | 5.43M | 2.11M | 683K |
| Interest Expense | 0 | 373K | 5.29M | 4.62M | 3.79M |
| Other Income / Expenses | 367K | 52.22M | (105K) | (1.98M) | (3.14M) |
| Income Before Tax | (340.1M) | (228.29M) | (276.11M) | (85.42M) | 32.72M |
| Pre-Tax Margin | -1672.1% | -359.1% | -3220.7% | -66.2% | 27.1% |
| Income Tax Expense | 46K | 12K | 15K | (12K) | 31K |
| Net Income | (340.14M) | (228.3M) | (276.13M) | (85.4M) | 32.69M |
| Net Margin | -1672.3% | -359.1% | -3220.9% | -66.2% | 27.1% |
| EPS (Basic) | (90.78) | (55.96) | (65.18) | (11.41) | 2.61 |
| EPS (Diluted) | (90.78) | (55.96) | (65.18) | (11.41) | 2.57 |
| 3.75M | 4.08M | 4.24M | 7.49M | 12.54M | |
| 3.75M | 4.08M | 4.24M | 7.49M | 12.72M |
ATRA Earnings Waterfall · TTM
NASDAQ:ATRA · Revenue to Net Income
Key Ratios
EPS$-0.67
Gross Margin90.7%
Net Margin-282.0%
P/E Ratio-5.5
P/S Ratio83.2
Analysis
$23.1M of revenue converted into -$9.5M of net income for the selected period. Gross margin is 90.7% and net margin is -282.0%, showing how much revenue survives after costs and taxes. EPS is $-0.67, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3 | S-3 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 26, 2026 |
How much revenue does ATRA generate?
Atara Biotherapeutics, Inc. (ATRA) reported $120.77M of revenue in fiscal 2025.
Is ATRA profitable?
Atara Biotherapeutics, Inc. (ATRA) reported $32.69M of net income, with a net margin of 27.1%.
Continue the stock analysis
Jump to another research area for this company.